NCT00277823已完成3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer25 个研究点 分布在 1 个国家目标入组 480 人开始时间: 2006年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 480
- 试验地点
- 25
- 主要终点
- The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.
研究概览
简要总结
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of major depressive disorder
- •Must be able to swallow tablets
- •Must be at least 18 years of age.
排除标准
- •Clinical diagnosis of other psychiatric disorders
- •Significant risk of suicide
- •Unstable medical conditions.
结局指标
主要结局
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.
次要结局
- Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.
研究者
研究点 (25)
Loading locations...
相似试验
已完成
3 期
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive DisorderDepressive Disorder, MajorNCT00300378Wyeth is now a wholly owned subsidiary of Pfizer480
已完成
3 期
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive DisorderDepressive DisorderDepressionMajor Depressive DisorderNCT00092911Wyeth is now a wholly owned subsidiary of Pfizer244
已完成
3 期
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00073762Wyeth is now a wholly owned subsidiary of Pfizer375
已完成
3 期
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00072774Wyeth is now a wholly owned subsidiary of Pfizer480
已完成
3 期
Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive DisorderMajor Depressive DisorderNCT00090649Wyeth is now a wholly owned subsidiary of Pfizer369